Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTACT2: Improving ICU outcomes by treating anaemia
ISRCTN20195735Phase 3Recruiting
- Sponsor
- University of Edinburgh & NHS Lothian ACCORD
- Start
- Oct 2025
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised trial of ferric carboxymaltose and darbepoetin alfa in anaemia (2 arms), sponsored by University of Edinburgh & NHS Lothian ACCORD. Primary endpoint: Physical health-related quality of life at 90 days. Started Oct 2025; status: recruiting.
02
Drugs
ferric carboxymaltosedarbepoetin alfa
03
Conditions
anaemia
Beyond the preview
Go deeper on ISRCTN20195735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN20195735.